肝脏 ›› 2026, Vol. 31 ›› Issue (9): 1263-1266.

• 病毒性肝炎 • 上一篇    下一篇

替诺福韦酯联合新生儿双重免疫阻断HBV母婴传播的效果与安全性观察

葛春燕, 曹霞, 优力吐孜阿依·阿地力, 尤春霞   

  1. 226000 南通 南通市第三人民医院妇产科(葛春燕,曹霞,尤春霞);
    845350 阿图什 新疆克孜勒苏柯尔克孜自治州人民医院产科(优力吐孜阿依·阿地力)
  • 收稿日期:2026-01-16 出版日期:2026-09-30 发布日期:2026-11-16
  • 通讯作者: 尤春霞,Email: youyu2008009@163.com

The effectiveness and safety of tenofovir disoproxil fumarate combined with neonatal dual immunoprophylaxis in preventing mother-to-child HBV transmission

Ge Chunyan1, Cao Xia1, Youlituziayi Adili2, You Chunxia1   

  1. 1. Department of Obstetrics and Gynecology, Nantong Third People's Hospital, Nantong 226000, China;
    2. Department of Obstetrics, People's Hospital of Kizilsu Kirghiz Autonomous Prefecture, Artux 845350, China
  • Received:2026-01-16 Online:2026-09-30 Published:2026-11-16
  • Contact: You Chunxia,Email: youyu2008009@163.com

摘要: 目的 探讨替诺福韦酯(TDF)联合新生儿双重免疫阻断HBV母婴传播的效果及安全性。方法 纳入2020年1月至2024年12月南通市第三人民医院分娩的HBsAg阳性孕妇及其所生婴儿共94例。联合阻断组(n=43)孕妇于孕中晚期口服TDF,标准阻断组(n=51)孕妇孕期未使用抗病毒药物;两组新生儿均于出生后12 h内注射乙型肝炎免疫球蛋白(HBIG),并按0、1、6个月程序完成乙型肝炎疫苗全程免疫。比较两组婴儿7~12月龄时HBV感染状态、新生儿免疫应答质量、母体病毒学及血生化指标动态变化,以及母婴安全性结局。结果 7~12月龄随访时,联合阻断组HBsAg及HBV DNA阳性率均为0,标准阻断组5例(9.8%)婴儿出现HBsAg和/或HBV DNA阳性(P<0.05)。联合阻断组婴儿抗-HBs高于标准阻断组,为356(210,620)mIU/mL比185(95,402)mIU/mL(P<0.05),高水平免疫应答(≥1 000 mIU/mL)比例更高(39.5%比19.6%,P<0.05)。分娩时联合阻断组HBV DNA水平低于标准阻断组,为(3.2±1.1)lg IU/mL比(6.9±0.7)lg IU/mL(P<0.05),病毒载量下降幅度更大,为(4.4±1.1)lg IU/mL比(0.6±0.2)lg IU/mL(P<0.05)。两组在母体肝肾功能异常、妊娠并发症及新生儿不良结局方面差异均无统计学意义(P>0.05)。结论 在高病毒载量HBsAg阳性孕妇中,TDF联合新生儿双重免疫阻断可显著降低HBV母婴传播发生率,并改善新生儿乙型肝炎疫苗免疫应答质量,且未增加母婴不良事件发生风险。

关键词: 乙型肝炎病毒, 替诺福韦酯, 乙型肝炎免疫球蛋白, 乙型肝炎疫苗, 母婴传播

Abstract: Objective To investigate the effectiveness and safety of tenofovir disoproxil fumarate (TDF) combined with neonatal dual immunoprophylaxis in preventing mother-to-child transmission of hepatitis B virus (HBV) among HBsAg-positive pregnant women with high viral loads. Methods A total of 94 HBsAg-positive pregnant women and their infants who received antenatal care and delivered at Nantong Third People's Hospital were enrolled. According to whether antiviral therapy was administered during pregnancy, all participants were divided into a combined prophylaxis group (n=43) and a standard prophylaxis group (n=51). The pregnant women in the combined group received oral TDF during mid-to-late pregnancy, whereas those in the standard group did not receive antiviral therapy. All newborns in both groups received hepatitis B immunoglobulin (HBIG) within 12 hours after birth and completed the full hepatitis B vaccination schedule at 0, 1, and 6 months. The HBV infection status of infants at 7~12 months of age, neonatal immune response, dynamic changes in maternal virological and biochemical parameters, and maternal and infant safety outcomes were compared between the two groups. Results At the 7~12 month follow-up, the rates of HBsAg and HBV DNA positivity were both 0 in the combined prophylaxis group, whereas 5 infants (9.8%) in the standard prophylaxis group were positive for HBsAg and/or HBV DNA (P<0.05). The median anti-HBs titer in infants was higher in the combined prophylaxis group than that in the standard group [356 (210, 620) mIU/mL vs. 185 (95, 402) mIU/mL, P<0.05], and the proportion of high-level immune response (≥1 000 mIU/mL) was greater (39.5% vs. 19.6%, P<0.05). At delivery, maternal HBV DNA levels were lower in the combined prophylaxis group than in the standard group [(3.2±1.1) lg IU/mL vs. (6.9±0.7) lg IU/mL, P<0.05], with a greater reduction in viral load [(4.4±1.1) lg IU/mL vs. (0.6±0.2) lg IU/mL, P<0.05]. There were no statistically significant differences between the two groups in maternal hepatic or renal dysfunction, pregnancy complications, or adverse neonatal outcomes (P>0.05). Conclusion Among HBsAg-positive pregnant women with high viral loads, TDF combined with neonatal dual immunoprophylaxis significantly reduces the rate of HBV mother-to-child transmission and improves the quality of neonatal immune responses to hepatitis B vaccination, without increasing maternal or neonatal adverse events, indicating a favorable clinical applicability.

Key words: Hepatitis B virus, Tenofovir disoproxil fumarate, Hepatitis B immunoglobulin, Hepatitis B vaccination, Mother-to-child transmission